A Phase 1, Single-Dose PK and Safety Study with NI-03 followed by a Phase 2, Randomized, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 Compared to Placebo in Subjects with Chronic Pancreatitis (IRB 228465)
|